Hepatitis B vaccine: a review of the clinical data to date. NLM AIDSLINE Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Hepatitis B vaccine: a review of the clinical data to date.

J Am Dent Assoc. 1985 Apr;110(4):624-8. Unique Identifier : AIDSLINE MED/85208780
McLean AA

Abstract: The CDC estimates that about 200,000 Americans become infected with HBV each year. About 200 die of fulminant hepatitis. Most importantly, 12,000 to 20,000 persons become chronically infected, placing themselves at increased risk of developing chronic sequelae such as cirrhosis and primary hepatocellular carcinoma and also putting their families and close personal contacts at risk of hepatitis B infection. An effective vaccine to protect against hepatitis B is currently available. The vaccine is produced according to a rigorous process known to kill HBV, the agent causing AIDS, and all other viruses known to be present in human plasma. Well-controlled clinical studies have shown the vaccine to be well tolerated, immunogenic, and highly effective in preventing hepatitis B. The benefits of vaccination are clear.
Keywords: Acquired Immunodeficiency Syndrome/TRANSMISSION Adolescence Adult Aged Antibody Formation Child Child, Preschool Follow-Up Studies Hepatitis B/PREVENTION & CONTROL Human Immunotherapy Infant Infant, Newborn Male Middle Age *Viral Hepatitis Vaccines/ADVERSE EFFECTS/IMMUNOLOGY JOURNAL ARTICLE REVIEW

KWDacquiredimmunodeficiencysyndrome/transmissionadolescenceadultagedantibodyformationchildchild,preschoolfollow-upstudieshepatitisb/prevention&controlhumanimmunotherapyinfantinfant,newbornmalemiddleageKWDviralhepatitisvaccines/adverseeffects/immunologyjournalarticlereview
850930
M8590086

Copyright © 1985 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1985. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .